Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Novo Nordisk to present 13 abstracts at ASH 2024 including phase 2/3 HIBISCUS trial of etavopivat

Written by | 9 Dec 2024

Novo Nordisk announced the presentation of 13 abstracts, three of which will be presented in oral sessions, at the upcoming 66th Annual Meeting and Exposition of the American Society… read more.

New insights on Haemophilia A and rare blood diseases to be presented by Sobi® at ASH 2024

Written by | 5 Dec 2024

New data from Sobi® and partners will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA (USA) from the… read more.

Daiichi Sankyo to present new clinical research across its oncology portfolio at ESMO 2024, ASH 2024 and SABCS 2024

Written by | 4 Dec 2024

Daiichi Sankyo will present new clinical research across its oncology portfolio with more than 45 abstracts in multiple types of solid and blood cancers at the 2024 ESMO… read more.

Roche presents long term outcomes and innovative therapies in hematology at ASH 2024

Written by | 2 Dec 2024

Roche announced  that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December… read more.

Novartis highlights transformative oncology research with 65+ abstracts at ASH and SABCS 2024

Written by | 26 Nov 2024

Novartis will present data from more than 65 abstracts, including investigator-initiated trials at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition and the 2024 San… read more.

Merck to showcase breakthrough data on hematologic malignancies at ASH 2024

Written by | 24 Nov 2024

Merck known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented… read more.

CG Oncology to present latest data on Cretostimogene Grenadenorepvec at SUO 2024 annual meeting

Written by | 23 Nov 2024

CG Oncology, Inc, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that four Trials… read more.

Aligos Therapeutics announces positive data on chronic hepatitis B and MASH treatments at AASLD 2024

Written by | 22 Nov 2024

Aligos Therapeutics, Inc. a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from… read more.

ASH 2024: Johnson & Johnson showcases innovations in multiple myeloma, B-cell malignancies, and autoimmune disorders

Written by | 21 Nov 2024

Johnson & Johnson announced more than 90 abstracts featuring data from the Company’s differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of Hematology (ASH)… read more.

BMS to showcase 90+ data presentations at ASH 2024, highlighting innovations in hematology and cell therapy

Written by | 20 Nov 2024

BMS announced the presentation of more than 90 data disclosures, including 18 oral presentations, across company-sponsored studies, investigator-sponsored studies and collaborations from its hematology and cell therapy research… read more.

GSK showcases advances in chronic Hepatitis B and Cholestatic Pruritus research at AASLD liver meeting 2024

Written by | 16 Nov 2024

GSK plc (will present 12 abstracts at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2024, taking place in San Diego, CA from 15-19… read more.

AASLD 2024: Mirum presents breakthrough data on Maralixibat and Volixibat for cholestatic liver diseases

Written by | 15 Nov 2024

Mirum Pharmaceuticals, Inc. (announced that it will present data at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting®, taking place November 15-19, 2024,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.